An emerging and complementary strategy to the targeting of PS described above using PS-targeting mAbs that is showing therapeutic promise in IO involves the targeting and inhibition of certain PS receptors, most notably Mertk and TIM-3 expressed on tumor-associated macrophages and/or on T cells. This evidence concerns the gene HAVCR2 and neoplasm.